This invention relates to the Production of New- (Fourth) Generation Clot-buster(s) comprising clinically beneficial thrombolytic molecules with enhanced half lives. These Fourth Generation Clot-buster(s) find wide application in medical sciences due to low dosage given in a single-shot bolus (a tremendous benefit of great clinical significance) as well as target (fibrin/clot) specificity.
Accessibility Controls
